STATEMENT ON A NONPROPRIETARY NAME ADOPTED BY THE USAN COUNCIL

USAN (JK-255)	AMUBARVIMAB
PRONUNCIATION	am” oo bar' vi mab
THERAPEUTIC CLAIM	Treatment of COVID-19

CHEMICAL NAMES

1. Immunoglobulin G1 [252-tyrosine,254-threonine,256-glutamic acid], anti-(severe acute respiratory syndrome coronavirus 2 spike glycoprotein receptor-binding domain) (human monoclonal BRII-196 γ1-chain), disulfide with human monoclonal BRII-196 κ-chain, dimer (Source : CAS)

2. Immunoglobulin G1-kappa,anti- Severe acute respiratory syndrome coronavirus (SARS-CoV) [Spike glycoprotein (Peplomer protein)]; *Homo sapiens* monoclonal antibody; γ1 heavy chain *Homo sapiens* (1-447) [VH(*Homo sapiens* (IGHV3-66*01 (96%) –(IGHD)-IGHJ6*01) [8.7.11] (1-117) - *Homo sapiens* IGHG1*01 {CH2[M^{22}>Y(252), S^{24}>T(254), T^{26}>E(256)]} (118-447) (220-214')-disulfide with κ light chain *Homo sapiens* (1'-214') [V-KAPPA (*Homo sapiens* IGKV3-20*01 –IGKJ2*01)[7.3.8] (1'-107') -*Homo sapiens* IGKC*01 (108'-214')], dimer (226-226'':229-229'')-bisdisulfide, produced in CHO-K1 cell line, glycoform alfa (Source : USAN Program chemical consultant)

STRUCTURAL FORMULA

Heavy chains X & X''

EVQLVESGGG	LVQPGGSLRL	SCAASGITVS	SNYMNWVRQA	PGKGLEWVSL	50
IYSGGSTYYA	DSVKGRFTIS	RDNSKNTLYL	QMNSLRAEDT	AVYHCARDLV	100
VYGMDVWGQG	TTVTVSSAST	KGPSVFPLAP	SSKSTSGGTA	ALGCLVKDYF	150
PEPVTVSWNS	GALTSGVHTF	PAVLQSSGLY	SLSSVVTVPS	SSLGTQTYIC	200
NVNHKPSNTK	VDKKVEPKSC	DKTHTCPPCP	APELLGGPSV	FLFPPKPKDT	250
LYITREPEVT	CVVVDVSHED	PEVKFNWYVD	GVEVHNAKTK	PREEQYNSTY	300
RVVSVLTVLH	QDWLNGKEYK	CKVSNKALPA	PIEKTISKAK	GQPREPQVYT	350
LPPSRDELTK	NQVSLTCLVK	GFYPSDIAVE	WESNGQPENN	YKTTPPVLDS	400
DGSFFLYSKL	TVDKSRWQQG	NVFSCSVMHE	ALHNHYTQKS	LSLSPGK	447

Light chain X' & X'''

EIVLTQSPGT	LSLSPGERAT	LSCRASQSVS	SSYLAWYQQK	PGQAPRLLIY	50'
GASSRATGIP	DRFSGSGSGT	DFTLTISRLE	PEDFAVYYCQ	QYGSSPTFGQ	100'
GTKLEIKRTV	AAPSVFIFPP	SDEQLKSGTA	SVVCLLNNFY	PREAKVQWKV	150'
DNALQSGNSQ	ESVTEQDSKD	STYSLSSTLT	LSKADYEKHK	VYACEVTHQG	200'
LSSPVTKSFN	RGEC				214'

Disulfide bridges location

22-95	22''-95''	23'-89'	23'''-89'''	134'-194'	134'''-194'''	144-200	144''-200'''
214'-220	214'''-220''	226-226''	229-229''	261-321	261''-321''	367-425	367''-425''

Glycosylation sites (N)

Asn-297 Asn-297''

MOLECULAR FORMULA	$C_{6378}H_{9906}N_{1710}O_{2010}S_{40}$ (nonglycosylated)
MOLECULAR WEIGHT	143.98 kDa

TRADEMARK	None as yet
SPONSOR	Brii Biosciences, Inc.
CODE DESIGNATIONS	BRII-196
CAS REGISTRY NUMBER	2509447-07-6
UNII	2AD5KH3SE4
WHO NUMBER	11988

gbk